ATE341316T1 - Kontrolle der wundvernarbung mit calmodulin- inhibitoren oder protein-kinase-c-inhibitoren - Google Patents

Kontrolle der wundvernarbung mit calmodulin- inhibitoren oder protein-kinase-c-inhibitoren

Info

Publication number
ATE341316T1
ATE341316T1 AT93918261T AT93918261T ATE341316T1 AT E341316 T1 ATE341316 T1 AT E341316T1 AT 93918261 T AT93918261 T AT 93918261T AT 93918261 T AT93918261 T AT 93918261T AT E341316 T1 ATE341316 T1 AT E341316T1
Authority
AT
Austria
Prior art keywords
inhibitors
wound
carring
protein kinase
calmodulin
Prior art date
Application number
AT93918261T
Other languages
English (en)
Inventor
Raphael C Lee
Original Assignee
Massachusetts Inst Technology
Arch Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Arch Dev Corp filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE341316T1 publication Critical patent/ATE341316T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93918261T 1992-07-20 1993-07-20 Kontrolle der wundvernarbung mit calmodulin- inhibitoren oder protein-kinase-c-inhibitoren ATE341316T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91641292A 1992-07-20 1992-07-20

Publications (1)

Publication Number Publication Date
ATE341316T1 true ATE341316T1 (de) 2006-10-15

Family

ID=25437230

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93918261T ATE341316T1 (de) 1992-07-20 1993-07-20 Kontrolle der wundvernarbung mit calmodulin- inhibitoren oder protein-kinase-c-inhibitoren

Country Status (5)

Country Link
EP (1) EP0651637B1 (de)
AT (1) ATE341316T1 (de)
AU (1) AU4777293A (de)
DE (1) DE69334068D1 (de)
WO (1) WO1994002130A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
FR2740335B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de lithium, d'etain, de zinc, de manganese ou d'yttrium comme antagoniste de substance p
AU755438B2 (en) * 1996-07-22 2002-12-12 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
EP1806131A3 (de) * 1996-07-22 2007-08-01 Renovo Limited Verwendung von Sex-Steroid-Funktionsmodulatoren zur Behandlung von Wunden und fibrotischen Erkrankungen
US6525100B1 (en) 1998-08-03 2003-02-25 W. Jerry Easterling Composition and method for treating peyronie's disease and related fibrotic tissue disorders
US6627663B2 (en) 1998-08-03 2003-09-30 W. Jerry Easterling Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method
US6031005A (en) * 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
RU2135195C1 (ru) * 1998-12-17 1999-08-27 Овсюк Валерий Григорьевич Способ получения материала, содержащего клетки предстательной железы, материал, содержащий клетки предстательной железы, и способы лечения фиброматоза матки, хронического простатита и нарушений мужской половой функции методом трансплантации
US6258802B1 (en) * 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
US7094431B2 (en) * 2000-10-12 2006-08-22 Mickey L. Peshoff Method of healing skin wounds in mammals and a composition therefor
US7767717B2 (en) 2003-06-09 2010-08-03 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3149180B2 (ja) * 1989-07-31 2001-03-26 マサチユセツツ・インスチチユート・オブ・テクノロジー 瘢痕治療のためのカルシウム拮抗薬の使用

Also Published As

Publication number Publication date
DE69334068D1 (de) 2006-11-16
EP0651637B1 (de) 2006-10-04
EP0651637A1 (de) 1995-05-10
AU4777293A (en) 1994-02-14
WO1994002130A1 (en) 1994-02-03

Similar Documents

Publication Publication Date Title
ATE341316T1 (de) Kontrolle der wundvernarbung mit calmodulin- inhibitoren oder protein-kinase-c-inhibitoren
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
ES2145744T3 (es) Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
DK0682514T3 (da) Anvendelse af lokalanæstetiske midler til fremstilling af et lægmiddel til behandling af bronchial astma
DE69838070D1 (de) Substituierte pyridin-derivate als entzündungshemmende mittel
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
ES2194025T3 (es) Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
ES2122076T3 (es) Derivados de nor-acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
ATE357216T1 (de) Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
ATE373679T1 (de) Antimikrobiell wirksames oder endotoxin neutralisierendes polypeptid
BR0111908A (pt) Composto, composição farmacêutica, uso do composto, e, método para o tratamento e/ou prevenção de distúrbios ou doenças
ATE337785T1 (de) Tiotropiumsalze zur behandlung von entzündlichen erkrankungen
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
DE69936381D1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
DE68912459D1 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
AR015966A1 (es) Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
DE69431623D1 (de) Hemmung, bekämpfung und regression der angiogenese mit hyaluronsäure oder hyaluronsäure und nsaid
ES2121103T3 (es) Antagonistas de la angiotensina ii para el tratamiento de enfermedades viricas.
BR0111852A (pt) Nova interferona para o tratamento de esclerose múltipla
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0012408A (pt) Métodos para induzir ou aumentar a migração celular, para reduzir ou inibir a migração celular, para induzir ou aumentar a cura de ferimento em um paciente, e para regular a expressão de pelo menos um gene de uma célula, e, uso de um agonista de fator de tecido
DE60134576D1 (de) Arzneimittel zur linderung von darmerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties